Archive · 23 Dec 2025
Emcure Pharma's Gujarat Plant Cleared by US FDA
Emcure Pharmaceuticals, an Indian company, got good news from the US FDA.
The FDA checked their medicine-making factory in Gujarat, India, and said everything was good.
They didn't find any problems, which means the factory follows all the rules.
This is great for Emcure because it shows their factory is safe and makes good medicines.
Also, Emcure just started selling a new medicine called Poviztra in India.
It helps people manage their weight.
The medicine comes in a pen and is priced at ₹8,790 per month.
After the good news, Emcure's stock price went up by 3.40%.
Emcure Pharmaceuticals received a 'No Action Indicated' (NAI) classification from the US FDA for its Gujarat plant.
The FDA conducted a surveillance inspection at the plant between October 6-10, 2025, with no observations.
The NAI classification means the FDA found no objectionable conditions and will not take regulatory action.
Emcure launched Poviztra, a semaglutide injection for weight management, becoming the first Indian company to distribute it.
Poviztra will be available in India in a once-weekly pen device with five dosage strengths, priced at ₹8,790 per month.
- Who
- Emcure Pharmaceuticals Ltd
- What
- Received Establishment Inspection Report (EIR) from US FDA for Gujarat plant, classified as 'No Action Indicated' (NAI)
- When
- Inspection conducted between October 6-10, 2025; announcement on December 23, 2025
- Where
- Kadu village, Surendranagar district, Gujarat, India
- Why
- To ensure compliance with US FDA's Current Good Manufacturing Practice (cGMP) requirements
- Company
- Emcure Pharmaceuticals Ltd
- Plant Location
- Kadu village, Surendranagar district, Gujarat
- Inspection Dates
- October 6-10, 2025
- Inspection Outcome
- No Action Indicated (NAI)
- New Drug
- Poviztra (semaglutide injection)
- Drug Availability
- Once-weekly pen device, five dosage strengths
- Drug Price
- ₹8,790 per month for four weekly doses
- Stock Price Change
- 3.40% increase to ₹1,426 on NSE